Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding

Phase 3 Completed 50 enrolled Autonomous University of Nuevo León

RandomizedParallel-groupDouble-blindDiagnostic

Summary

A prospective, randomized, double-blind study will be conducted, including all patients with upper gastrointestinal bleeding, defined as vomiting blood or black bowel movements, within 24 hours prior to admission. Patients will be randomized to receive intravenous metoclopramide 20 mg or placebo, a placebo is a look-alike substance that contains no active drug. Then endoscopy will be performed in the following 120 minutes, evaluating endoscopic visualization with the modified Avgerinos scale.

Timeline

Start: 2023-03-01
Primary completion: 2024-06-01
Completion: 2024-06-01

Publications

Background Estes DJ, Berera S, Deshpande AR, Sussman DA. Re-Visiting Metoclopramide to Optimize Visualization with Gastrointestinal Bleeding - Mobilizing Existing Data. Clin Endosc. 2019 Sep;52(5):516-517. doi: 10.5946/ce.2019.046. Epub 2019 Jul 16. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metoclopramide	Small molecule	20 mg	Intravenous

Indications

No indication recorded.